Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008).
DRUG INFORMATION ASSOCIATION (DIA) POSTPONES 3RD ANNUAL CONFERENCE ON DRUG DISCOVERY AND CLINICAL DEVELOPMENT IN INDIA
WHO:
Drug Information Association (DIA)
WHAT:
3rd Annual Conference on Drug Discovery and Clinical Development in India
WHERE:
Renaissance Mumbai Hotel and Convention Centre
Mumbai, India
WHEN:
December 7-10, 2008
WHY:
Due to the tragic events that have taken place in Mumbai, DIA has postponed its 3rd Annual Conference on Drug Discovery and Clinical Development in India (December 7-10, 2008). The DIA Board of Directors, operational staff, and members and volunteers express their sympathies to the many people affected by the past week’s events. DIA is currently making plans to present this conference in February 2009 and will contact you with updated information about specific dates as soon as this information becomes available.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.